BBO-11818 is a selective, orally bioavailable non-covalent inhibitor that targets KRAS in both the ON and OFF states, has ...

Direct multi-KRAS inhibitors, QTX3034 and QTX3544, exhibit potent activity against established and novel resistance mechanisms to ...

DUBLIN--(BUSINESS WIRE)--The "Global KRAS Inhibitors Market & Clinical Trials Future Outlook 2030" report has been added to ResearchAndMarkets.com's offering. With the ubiquitous prevalence of cancer ...

HIGHLIGHTSAmplia’s lead drug narmafotinib enhances the activity of kRAS inhibitors in multiple preclinical cancer models presented at US ...

A previous study showed a confirmed objective response rate of 42.9% with the KRAS G12C inhibitor adagrasib in previously treated patients with NSCLC. In this phase III trial, median progression-free ...

SAN DIEGO--(BUSINESS WIRE)--Alterome Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the development of next-generation, small molecule targeted therapies for the treatment ...

ISM6166 was nominated as a PCC as an oral, broad-spectrum pan‑KRAS ON/OFF inhibitor, designed to overcome resistance ...

A China-developed KRAS inhibitor led to objective responses in half of patients with previously treated KRAS-mutant non-small cell lung cancer (NSCLC), a prospective non-randomized trial showed.

BEIJING, SHANGHAI and BOSTON, Dec. 21, 2025 /PRNewswire/ -- Jacobio Pharma (1167.HK,) today announced that it has entered an agreement with AstraZeneca for its proprietary Pan-KRAS inhibitor JAB-23E73 ...

Among patients with KRAS G12C mutations, candidate primary resistance mutations were detected in many patients with colorectal cancer (CRC) and pancreatic ductal adenocarcinoma (PDAC), which may limit ...

AstraZeneca has fronted $100 million to head deeper into the KRAS space, securing the rights to a clinical-stage, multitarget asset from China’s Jacobio Pharma. U.K.-based AstraZeneca has scored the ...